Oxford Nanopore Technologies PLC (ONT) AI Stock Analysis

• Market Cap: £1.34B
• Dividend Yield: N/A
• Average Volume (3M): 1.51M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.15
• Revenue Growth: 22.03%
• EPS Growth: 20.01%
• Country: UK
• Employees: 1,382
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 966,057,000
• 10 Day Avg. Volume: 1,415,809
• 30 Day Avg. Volume: 1,510,061
• PEG Ratio: 0.50
• Price to Book (P/B): 1.97
• Price to Sales (P/S): 6.31
• P/FCF Ratio: -9.34
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £178.25
• Price Target Upside: 39.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: 143.00p ▲(11.72% Upside)

The overall stock score of 51 reflects a combination of financial challenges and technical weaknesses, offset by positive earnings guidance and corporate governance initiatives. The company's revenue growth and strategic focus on improving profitability are promising, but current financial and market conditions pose significant risks.

Positive Factors

Consistent revenue growth

Sustained top-line growth provides a structural foundation for investment in R&D, manufacturing scale and market expansion. Continued revenue momentum supports recurring consumable sales and platform adoption, improving the firm's ability to fund long-term initiatives without relying solely on external capital.

Strong equity base / balance sheet

A high equity ratio indicates low leverage and greater solvency, giving management flexibility to fund R&D and capex, withstand cyclical biotech spend cycles, and pursue strategic partnerships or acquisitions without immediate refinancing pressure that could dilute strategic choices.

Diversified, recurring revenue model

Multiple revenue streams—hardware sales plus consumable and software revenues and licensing—create recurring, sticky cash flow potential. Consumable-driven economics and partner collaborations support long-term customer retention and margin leverage as installed base grows.

Negative Factors

Negative operating cash flow

Persistently negative operating cash flow constrains the firm's ability to self-fund growth and R&D, increasing reliance on external financing. Over months this can pressure strategic flexibility, raise financing costs, and heighten dilution or covenant risks if not reversed.

Ongoing unprofitability and negative margins

Sustained negative margins mean the business has yet to demonstrate scalable profitability. This limits free cash generation, elevates the need for continual capital raises, and leaves long-term returns dependent on structural margin improvement rather than just revenue growth.

Segment and regional headwinds (gaming, China)

Persistent underperformance in specific segments and a key geography reduces revenue diversification and can slow adoption in important markets. Structural challenges in China and gaming weaken revenue predictability and may require targeted strategy or investment to restore growth there.

Oxford Nanopore Technologies PLC Business Overview & Revenue Model

Company Description

Oxford Nanopore Technologies plc develops and commercializes a technology platform using nanopore-based sensing for the analysis of various types of molecules. The company offers MinION, a portable device for deoxyribonucleic acid and ribonucleic acid sequencing; GridION, a self-contained benchtop device for running and analyzing up to five MinION or Flongle flow cells; MinION Mk1C for basecalling and data analysis, touchscreen operation, and wireless connectivity; Flongle, an adapter for use in MinION or GridION devices to attach a Flongle flow cell; GridION Mk1, a benchtop nanopore sequencer; PromethION 2 Solo and PromethION 2, a low-cost access to high-yield PromethION sequencing; PromethION 24 and PromethION 48 benchtop nanopore-based sequencers for multiple users to deliver multi-sample and multi-experiment sequencing results; and VolTRAX, an USB-powered device, which automates laboratory processes upstream of nanopore sequencing. It also provides MinKNOW, a software that offers data acquisition, real-time analysis and feedback, local basecalling, and data streaming; Basecalling tools to determine the identity and order of bases on the DNA/RNA molecule; EPI2ME, a cloud-based data analysis platform for end-to-end analysis of nanopore data in real time; and EPI2ME Labs, a bioinformatics solution to assist users in developing their skills and confidence in the analysis of their nanopore-based sequencing data. In addition, the company is developing MinION Mk1D; Ubi; Plongle; and SmidgION products. It sells its products online. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies Limited in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is based in Oxford, the United Kingdom.

How the Company Makes Money

Oxford Nanopore Technologies generates revenue primarily through the sale of its sequencing devices, consumables, and associated software. The company's revenue model encompasses multiple streams, including direct sales of hardware, ongoing consumable sales, and support services for its sequencing platforms. Additionally, ONT licenses its technology and provides collaborative services for research and development projects. Significant partnerships with academic institutions, healthcare organizations, and pharmaceutical companies enhance its earnings by expanding its customer base and facilitating the adoption of its sequencing technology in various fields. The company also benefits from grants and funding aimed at advancing genomic research and innovation.

Oxford Nanopore Technologies PLC Financial Statement Overview

Summary

Oxford Nanopore Technologies PLC demonstrates revenue growth and a strong equity position, crucial for long-term sustainability. Nonetheless, persistent losses and negative cash flows highlight profitability and cash management challenges that require strategic attention to improve financial health.

Income Statement

Oxford Nanopore Technologies PLC shows a consistent revenue growth trend, with a 7.95% increase from 2023 to 2024. However, the company remains unprofitable, reflected by negative EBIT and net income margins, indicating ongoing challenges in cost management and profitability.

Balance Sheet

The company maintains a solid equity base with an equity ratio of 79.03% in 2024, suggesting financial stability. However, the high debt-to-equity ratio of 0.08 indicates potential leverage concerns, although manageable due to strong equity.

Cash Flow

Operating cash flow remains negative, highlighting cash management challenges. Despite an improvement in free cash flow to net income ratio, free cash flow remains negative, suggesting ongoing cash flow constraints that may impact future growth initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	151.91M	183.19M	169.67M	198.60M	133.66M	113.86M
Gross Profit	86.63M	105.39M	90.48M	123.81M	73.19M	46.88M
EBITDA	-101.49M	-93.09M	-105.71M	-49.67M	-140.34M	-55.07M
Net Income	-107.44M	-146.19M	-154.51M	-91.03M	-167.61M	-61.24M
Balance Sheet
Total Assets	671.70M	742.05M	777.06M	823.89M	841.87M	281.21M
Cash, Cash Equivalents and Short-Term Investments	331.80M	338.37M	270.05M	476.19M	618.47M	80.86M
Total Debt	44.10M	45.96M	41.66M	34.10M	24.80M	23.63M
Total Liabilities	148.30M	155.71M	133.21M	130.33M	137.89M	95.28M
Stockholders Equity	523.40M	586.34M	643.85M	693.56M	703.98M	185.93M
Cash Flow
Free Cash Flow	-84.45M	-123.83M	-164.59M	-91.62M	-84.64M	-90.28M
Operating Cash Flow	-74.11M	-109.89M	-137.30M	-49.39M	-53.83M	-63.81M
Investing Cash Flow	50.76M	15.03M	-61.79M	-65.79M	-161.99M	-26.94M
Financing Cash Flow	72.15M	73.58M	64.73M	-13.71M	622.90M	158.58M

Oxford Nanopore Technologies PLC Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 128.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:ONT, the sentiment is Positive. The current price of 128 is below the 20-day moving average (MA) of 129.26, below the 50-day MA of 132.24, and below the 200-day MA of 144.06, indicating a neutral trend. The MACD of 0.66 indicates Negative momentum. The RSI at 65.50 is Neutral, neither overbought nor oversold. The STOCH value of 87.60 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:ONT.

Oxford Nanopore Technologies PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OXB	56 Neutral	£841.65M	-20.82	-74.64%	―	55.44%	75.77%
PRTC	55 Neutral	£303.56M	8.99	15.04%	―	1231.50%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ONT	51 Neutral	£1.34B	-9.43	-26.01%	―	22.03%	20.01%
SCLP	49 Neutral	£103.78M	-7.58	―	―	―	-94.12%
AVCT	42 Neutral	£273.06M	―	―	―	―	―
4BB	41 Neutral	£95.23M	-6.19	-209.34%	―	198.49%	-26.66%

Oxford Nanopore Technologies PLC Corporate Events

Oxford Nanopore to Showcase Genomic Technology at Key January Investor Conferences

Oxford Nanopore Technologies plc will engage with investors at two major January events, the 44th Annual J.P. Morgan Healthcare Conference in San Francisco and the dbAccess UK & Ireland Conference in London, featuring a presentation, Q&A and investor meetings. The planned outreach, including a publicly accessible webcast of the J.P. Morgan session, underscores the company’s efforts to raise its visibility in the healthcare and life sciences investment community and to reinforce its positioning as a key player in real-time genomic and molecular analysis technologies.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Updates Share Capital and Voting Rights After Option Exercises

Oxford Nanopore Technologies has issued 190,696 new ordinary shares following the exercise of employee share options and the operation of certain remuneration schemes, with the new shares admitted to the FCA’s Official List and to trading on the London Stock Exchange’s main market under the company’s existing block listing facility. Following this allotment, Oxford Nanopore’s issued share capital stands at 966,057,025 ordinary shares with no treasury shares held, establishing the updated total voting rights figure that shareholders must use to assess disclosure thresholds under UK transparency rules and leaving headroom for the admission of a further 6,468,179 shares under the current block listing.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Technologies Announces Share Incentive Plan Transaction

Oxford Nanopore Technologies PLC announced a transaction involving the Share Incentive Plan (SIP) for its Chief Financial Officer, Nick Keher. On December 12, 2025, 118 ordinary shares were purchased on behalf of Keher, with an equal number of matching shares issued under the SIP. This move aligns with the company’s obligations under the UK Market Abuse Regulation, potentially impacting stakeholder confidence and reinforcing the company’s commitment to employee investment.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £1.70 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Engages Shareholders and Appoints New CEO for Strategic Growth

Oxford Nanopore Technologies has engaged with major shareholders following its 2025 AGM to understand their concerns regarding a specific resolution. The company is committed to refining its strategic planning to maximize long-term value, and has appointed Francis Van Parys as CEO to lead the next phase of growth and enhance its commercial strategy.

The most recent analyst rating on (GB:ONT) stock is a Hold with a £128.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Appoints New CEO to Drive Growth

Oxford Nanopore Technologies plc has announced the appointment of Francis Van Parys as the new Chief Executive Officer, effective March 2, 2026. Van Parys, who brings extensive experience from leading roles at Radiometer, Cytiva, and GE Healthcare, will succeed Gordon Sanghera, the company’s founding CEO. This leadership transition is expected to drive the next phase of growth for Oxford Nanopore, leveraging Van Parys’ expertise in scaling innovation-driven businesses. The company anticipates continued expansion and innovation under his leadership, aiming to enhance operational execution and deliver value to stakeholders.

The most recent analyst rating on (GB:ONT) stock is a Hold with a £128.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Expands Share Capital with New Equity Issuance

Oxford Nanopore Technologies PLC announced the issuance of 381,797 ordinary shares following the exercise of options and remuneration schemes, which have been admitted to trading on the London Stock Exchange. This increases the company’s issued share capital to 965,866,329 ordinary shares, impacting shareholder voting rights and potentially influencing market perceptions of the company’s growth and financial strategies.

The most recent analyst rating on (GB:ONT) stock is a Hold with a £150.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Technologies to Engage in December Investor Conferences

Oxford Nanopore Technologies announced its participation in several investor conferences in December, including the Citi 2025 Global Healthcare Conference, the 37th Annual Piper Sandler Healthcare Conference, and the Berenberg European Conference. These events will feature analyst-led discussions and investor meetings, providing the company an opportunity to engage with stakeholders and potentially strengthen its market position.

The most recent analyst rating on (GB:ONT) stock is a Hold with a £150.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Technologies Announces Share Incentive Plan Transaction

Oxford Nanopore Technologies PLC announced a transaction under its Share Incentive Plan (SIP) involving Nick Keher, the company’s Chief Financial Officer. On 12 November 2025, Keher was awarded 104 Partnership Shares, purchased at £1.44 each, and 104 Matching Shares, issued at no cost, as part of the company’s efforts to align employee interests with corporate performance. This transaction, conducted on the London Stock Exchange, reflects the company’s commitment to incentivizing its management team and could enhance stakeholder confidence in the company’s governance practices.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £175.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Delays Investor Event Amid CEO Transition, Reaffirms Revenue Guidance

Oxford Nanopore Technologies has postponed its virtual investor event due to the ongoing CEO succession process, while reaffirming its full-year 2025 revenue growth guidance at the top end of 20-23%. This decision reflects the company’s strategic focus on leadership transition while maintaining strong financial performance expectations, which may reassure stakeholders about its stability and future direction.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £175.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Expands Share Capital with New Equity Issue

Oxford Nanopore Technologies PLC announced the issuance of 1,704,751 ordinary shares following the exercise of options and remuneration schemes, which are now listed on the London Stock Exchange. This increases the company’s total voting rights to 965,484,532, impacting shareholder calculations under FCA rules.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £175.00 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Technologies to Host Investor Event and Participate in Conferences

Oxford Nanopore Technologies has announced an investor event on November 14, 2025, to discuss its commercial strategy and growth opportunities. Additionally, the company will participate in the J.P. Morgan UK Leaders Conference and the Jefferies Global Healthcare Conference in November, offering presentations and meetings with investors. These events aim to enhance investor understanding of the company’s market potential and strategic direction.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £2.40 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.

Oxford Nanopore Technologies Announces Share Incentive Plan Transaction

Oxford Nanopore Technologies PLC announced a transaction involving the Share Incentive Plan (SIP) where 100 ordinary shares were awarded to Nick Keher, the company’s Chief Financial Officer, as part of the SIP. This transaction, which took place on 14 October 2025, involved the purchase of shares using the employee’s gross salary and the issuance of matching shares by the company, reflecting its commitment to employee investment and engagement.

The most recent analyst rating on (GB:ONT) stock is a Buy with a £2.40 price target. To see the full list of analyst forecasts on Oxford Nanopore Technologies PLC stock, see the GB:ONT Stock Forecast page.